Results 21 to 30 of about 3,840 (115)

Contribution of Glutamatergic and GABAergic Mechanisms to the Plasticity‐Modulating Effects of Dopamine in the Human Motor Cortex

Human Brain Mapping, Volume 46, Issue 3, February 15, 2025.
Background: Dopamine modulates cortical excitability and plasticity by influencing glutamate and GABA receptor activity. This study investigates the impact of general dopaminergic activation and D1‐ and D2‐like receptor modulation on transcranial direct current stimulation (tDCS)‐induced plasticity in humans.Methods:• Pharmacological intervention: l ...
Elham Ghanavati, Mohammad Ali Salehinejad, Marie C. Beaupain, Lorena Melo, Amba Frese, Min‐Fang Kuo, Michael A. Nitsche   +6 more
wiley   +1 more source

The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors

Brain Pathology, Volume 35, Issue 1, January 2025.
Abstract The vast majority of pituitary neuroendocrine tumors (PitNETs) are benign and slow growing with a low relapse rate over many years after surgical resection. However, about 40% are locally invasive and may not be surgically cured, and about one percentage demonstrate an aggressive clinical behavior.
Olivera Casar‐Borota, Pia Burman, M. Beatriz Lopes   +2 more
wiley   +1 more source

Neuroendocrine tumours and pregnancy: Real‐world data from an European Neuroendocrine Tumour Centre of Excellence

Journal of Neuroendocrinology, Volume 37, Issue 1, January 2025.
Abstract Neuroendocrine neoplasms (NENs) arise from the diffuse endocrine system and have been considered to be rare. However, the incidence and prevalence of these tumours have increased in recent years, and they are being seen in younger patients including women in the reproductive age group.
Gowri M. Ratnayake, Kalyan Mansukhbhai Shekhda, Thomas Glover, Yasser Al‐Obudi, Aimee Hayes, Panagiotis Armonis, Dalvinder Mandair, Bernard Khoo, TuVinh Luong, Christos Toumpanakis, Ashley Grossman, Martyn Caplin   +11 more
wiley   +1 more source

Time‐dependent MR diffusion analysis of functioning and nonfunctioning pituitary adenomas/pituitary neuroendocrine tumors

Journal of Neuroimaging, Volume 35, Issue 1, January/February 2025.
Background and Purpose Differentiation between functioning and nonfunctioning pituitary adenomas/pituitary neuroendocrine tumors (PAs) is clinically relevant. The goal of this study was to determine the feasibility of using time‐dependent diffusion MRI (dMRI) for microstructural characterization of PAs.
Kiyohisa Kamimura, Tomohiro Tokuda, Junki Kamizono, Tsubasa Nakano, Tomohito Hasegawa, Masanori Nakajo, Fumitaka Ejima, Fumiko Kanzaki, Koji Takumi, Masatoyo Nakajo, Shingo Fujio, Ryosuke Hanaya, Akihide Tanimoto, Takashi Iwanaga, Hiroshi Imai, Thorsten Feiweier, Takashi Yoshiura   +16 more
wiley   +1 more source

Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients [PDF]

The Journal of Clinical Endocrinology & Metabolism, 1998
Cabergoline is a new, long acting, dopamine agonist that is more effective and better tolerated than bromocriptine in patients with hyperprolactinemia. Because dopamine agonists still have a place in the medical management of acromegaly, cabergoline might be a useful treatment.
Abs, Roger, Verhelst, J., Maiter, Dominique, van Acker, K., Nobels, F., Coolens, J.-L., Mahler, Charles, Beckers, A.   +7 more
openaire   +5 more sources

Thyroid‐Stimulating Hormone‐Secreting Pituitary Adenoma: Two Cases With Challenging Diagnosis and Management

Case Reports in Endocrinology, Volume 2025, Issue 1, 2025.
Background: Thyroid‐stimulating hormone (TSH)‐secreting pituitary adenomas (TSHomas) are very rare pituitary tumors causing central hyperthyroidism. Most are macroadenomas (≥ 10 mm) with local and systemic comorbidities at diagnosis. The atypical changes in thyroid function tests (TFTs) may be subtle and are often initially missed, while over‐secretion
Elodie Gruneisen, Juan Andres Rivera, Osamu Isozaki   +2 more
wiley   +1 more source

Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients [PDF]

Obstetrical & Gynecological Survey, 1999
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the ...
Verhelst, Johan, Abs, Roger, Maiter, Dominique, Van Den Bruel, Annick, Vandeweghe, Mark, Velkeniers, Brigitte, Mockel, Jean, Lamberigts, Gerard, Petrossians, Patrick, Coremans, Peter, Mahler, Charles, Stevenaert, Achille, Verlooy, Jan, Raftopoulos, Christian, Beckers, Albert   +14 more
openaire   +5 more sources

Arrested Puberty in a Young Adult With a Macroprolactinoma: Case Report and Literature Review

Case Reports in Endocrinology, Volume 2025, Issue 1, 2025.
Prolactinoma is the most common pituitary tumor, with clinical presentations varying according to sex, age of onset, tumor size, and prolactin (PRL) levels. These tumors are rare in the pediatric and adolescent populations. Hyperprolactinemia leads to hypogonadotropic hypogonadism, resulting in reproductive, metabolic, sexual, and skeletal consequences
Sánchez M., Otazú M., Furtenbach P., Piñeyro M., Osamu Isozaki   +4 more
wiley   +1 more source

Generalized Fused Lasso for Treatment Pooling in Network Meta‐Analysis

Statistics in Medicine, Volume 43, Issue 30, Page 5635-5649, 30 December 2024.
ABSTRACT This work develops a generalized fused lasso (GFL) approach to fitting contrast‐based network meta‐analysis (NMA) models. The GFL method penalizes all pairwise differences between treatment effects, resulting in the pooling of treatments that are not sufficiently different.
Xiangshan Kong, Caitlin H. Daly, Audrey Béliveau   +2 more
wiley   +1 more source

Pharmacological effects of cabergoline against parkinsonism.

Folia Pharmacologica Japonica, 2001
The pharmacological effects of cabergoline, a novel ergot alkaloid, against parkinsonism were assessed by comparing its effects with those of bromocriptine and pergolide. The affinities of cabergoline and pergolide for the D2 receptor were about the same, about 7 times stronger than that of bromocriptine.
Masami Kojima, Kiyoshi Ichikawa
openaire   +3 more sources